Home›Stocks›KNSA

KNSA — structural market context

Kiniksa Pharmaceuticals Intern

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Nov 2. Each line shows the earlier value, the later value and their dates.

Price

Change from the Oct 30 close to the Nov 2 close: −1.56%.

Volume

1.15× its 20-session average on Nov 2.

Includes pre- and post-market trading.

Short interest

Short interest 3.8M shares (settlement Oct 15) vs 3.8M (Sep 30).

No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 2 days with fails, largest 10K shares on Sep 17.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 4 days with fails, largest 178 shares on Sep 3.

No new file loaded in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

Events · early sample

None recorded in this window.

KNSA events and their magnitude

Latest SEC filing in the event study

8-K 2.02 · Earnings release · filed 2026-10-27 · View on sec.gov ↗

…

How the Event Study works →

KNSA short interest & days to cover

SHARES SHORT

3.8M

% OF FLOAT

5.0%

DAYS TO COVER

6.8

CHANGE VS PRIOR

-0.4%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (19d ago)

How short interest and days to cover are measured →

KNSA fails-to-deliver (FTD)

Settlement date	Failed shares	Price
2026-09-22 · 42d	2	$78.13
2026-09-17 · 47d	10K	$77.62
2026-09-09 · 55d	1	$77.09

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

How fails-to-deliver are reported →

KNSA insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 1 sale

Insider	Type	Shares	Value	Filed
Megna Michael R · officer: CHIEF ACCOUNTING OFFICER	Sale (S)	5K	$369K	2026-09-03

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Form 4 transaction codes explained →

KNSA analyst ratings

Firm	Action	Rating	Published
Goldman Sachs	hold	Buy	2026-10-28
Goldman Sachs	price_target	—	2026-10-28

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is KNSA's short interest?

As of the FINRA settlement date 2026-10-15, KNSA had 3.8M shares sold short — 5.0% of its float, with 6.8 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.

Are insiders buying KNSA?

In the last 12 months of SEC Form 4 filings, KNSA recorded 0 insider purchases and 1 sale reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.

What do analysts say about KNSA?

The most recent action: Goldman Sachs hold to Buy on 2026-10-28. Rating actions are shown as published by the firms; they are not graded here.

Is this page telling me to buy or sell KNSA?

No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.

All covered stocks Short Interest & FTD tracker Insider Buying tracker The platform

Other companies in the same SEC industry: Pharmaceutical Preparations

ACRS · Aclaris Therapeutics, Inc.ALNY · Alnylam Pharmaceuticals, Inc.DYN · Dyne Therapeutics, Inc.LQDA · Liquidia Corporation NVS · Novartis AG PHAR · Pharming Group N.V. ADS, each

Industry: SIC code 2834 as recorded on SEC EDGAR.

All tickers starting with K →

KNSA: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.